{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/management/management/","result":{"pageContext":{"chapter":{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 883078b9-c8d3-4acf-9a68-46b2f58ec9a0 --><h2>Scenario: Management</h2><!-- end field 883078b9-c8d3-4acf-9a68-46b2f58ec9a0 -->","summary":"Covers the management of people with hyperthyroidism, subclinical hyperthyroidism, and Graves' orbitopathy.","htmlStringContent":"<!-- begin item 15f33ca3-54db-425a-a2fc-0a57b9ce4dfb --><!-- begin field a0caf5ab-450f-4bd7-a110-acbc0159e9ac --><p>From age 18 years onwards.</p><!-- end field a0caf5ab-450f-4bd7-a110-acbc0159e9ac --><!-- end item 15f33ca3-54db-425a-a2fc-0a57b9ce4dfb -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c1c7d0e2-e104-5501-90c4-ec0f5d4c1174","slug":"managing-overt-hyperthyroidism","fullItemName":"Managing overt hyperthyroidism","depth":3,"htmlHeader":"<!-- begin field 943725e3-56b0-4def-bfd8-be97a739ea20 --><h3>How should I manage a person with overt hyperthyroidism (non-pregnant)?</h3><!-- end field 943725e3-56b0-4def-bfd8-be97a739ea20 -->","summary":null,"htmlStringContent":"<!-- begin item b1ea73cb-1948-4d72-a4ab-b99ca212f891 --><!-- begin field 2ae2cd05-311f-456d-90bb-6e6fa09272b8 --><p><strong>If a person has a confirmed diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">overt hyperthyroidism</a> following <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">thyroid function tests</a> (TFTs):</strong></p><ul><li><strong>Arrange emergency admission </strong>if there are symptoms suggesting a serious complication, such as <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">thyrotoxic crisis</a>.</li><li><strong>Arrange urgent referral to an endocrinologist </strong>for specialist assessment if a <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">pituitary or hypothalamic disorder</a> is suspected, depending on clinical judgement.</li><li><strong>Arrange referral or discuss with an endocrinologist the need for <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#specialist-investigations-management\">specialist investigations and management</a>,</strong> for all other people with new-onset hyperthyroidism, the urgency depending on clinical judgement. In particular, if the person:<ul><li>Has a goitre, nodule, or structural change in the thyroid gland, if malignancy is suspected, refer using a suspected cancer pathway. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/neck-lump/\">Neck lump</a> and <a class=\"topic-reference external-reference\" href=\"/topics/head-neck-cancers-recognition-referral/\">Head and neck cancers - recognition and referral</a> for more information.<ul><li>Note: TFTs are usually normal in people with thyroid cancer.</li></ul></li><li>Is planning a pregnancy, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/pre-conception-pregnancy-postpartum/#managing-women-pre-conception\">Managing women pre-conception</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/pre-conception-pregnancy-postpartum/\">Scenario: Pre-conception, pregnancy, and postpartum</a> for more information.</li></ul></li><li><strong>While awaiting specialist endocrinology assessment:</strong><ul><li>Consider prescribing a beta-blocker and titrating the dose depending on clinical response, to provide relief of adrenergic <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">symptoms</a> (such as palpitations, tremor, tachycardia, or anxiety).<ul><li>If there is any uncertainty about starting a beta-blocker in primary care, seek specialist advice.</li><li>Adjust the beta-blocker dose according to symptom response, and aim to taper and stop the drug once the person is asymptomatic and euthyroid.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/beta-blockers/\">Beta-blockers</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>Consider seeking specialist advice<strong> </strong>about starting antithyroid drugs such as <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/carbimazole/\">carbimazole</a> in primary care for people:<ul><li>With troublesome symptoms despite treatment with a beta-blocker, or if a beta-blocker is not tolerated or contraindicated. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/beta-blockers/\">Beta-blockers</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/\">Prescribing information</a> for more information.</li><li>At risk of a <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">complication</a> from hyperthyroidism.</li><li>Taking a <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/causes/\">drug treatment</a> such as amiodarone or lithium. Liaison between the specialist prescribing the drug and an endocrinologist may be needed.</li></ul></li></ul></li><li><strong>Offer advice on sources of information and support,</strong> such as:<ul><li>The British Thyroid Foundation leaflets <a href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=87a94572-8698-402e-9e1d-f305b905b089\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"e405521d-0305-4968-889d-ab50009b4bd5\">Your guide to hyperthyroidism</a>, <a href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=98f12be4-fa91-402a-847a-a3ae22fa33bd\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"90bb81af-1bca-42d0-b8fc-ab50009b4bf0\">Your guide to thyroid function tests</a>, and <a href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=79ea5976-a0c0-4b92-aa54-528d1158cdb5\" data-hyperlink-id=\"8f86ddab-cfb6-4fe7-88c1-abc700bf0542\">Your guide to antithyroid drug therapy to treat hyperthyroidism</a>.</li></ul></li></ul><!-- end field 2ae2cd05-311f-456d-90bb-6e6fa09272b8 --><!-- end item b1ea73cb-1948-4d72-a4ab-b99ca212f891 -->","subChapters":[{"id":"3025443c-3f16-5f92-8181-0ce498d6d6c6","slug":"specialist-investigations-management","fullItemName":"Specialist investigations and management","depth":4,"htmlHeader":"<!-- begin field c68c1790-c6d9-442c-b932-58fb8369adfa --><h4>Specialist investigations and management</h4><!-- end field c68c1790-c6d9-442c-b932-58fb8369adfa -->","summary":null,"htmlStringContent":"<!-- begin item 7b5838b3-65e5-408e-bed3-c7b33c82c960 --><!-- begin field 128f8631-0528-4d80-b4ca-a7b6d83ca41b --><p><strong>The investigation and management of people with thyrotoxicosis depends on the person's age, underlying diagnosis, degree of TSH suppression, clinical presentation, co-existing conditions, and patient preference </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>]<strong>.</strong></p><p><strong>Specialist investigations</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><ul><li>Thyroid ultrasound scan with doppler may be used. Doppler provides relevant information on thyroid size, echogenicity, presence/absence of nodules, and vascularization.</li><li>If thyroid-stimulating hormone (TSH)-receptor antibodies <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">TRAbs</a> are not present, a scan of radionuclide thyroid uptake (with radioiodine or technetium) can help distinguish different causes of hyperthyroidism. This typically shows a diffuse pattern of uptake in Graves' disease, compared with one or more 'hot' nodules in toxic nodular hyperthyroidism. All types of thyroiditis are associated with reduced or absent uptake of radioisotope into the thyroid.</li><li>Measurement of 24-hour urinary iodine excretion may help to confirm suspected excessive iodine intake.</li></ul><p><strong>Antithyroid drugs</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><ul><li>Antithyroid drug treatments (carbimazole and propylthiouracil) are used to decrease thyroid hormone synthesis, by acting as a preferred substrate for iodination by thyroid peroxidase, the key enzyme in thyroid hormone production. Propylthiouracil is usually not used first-line, due to a small risk of severe liver injury, except in certain circumstances such as pre-pregnancy or the first trimester of pregnancy, or for specialist treatment of thyrotoxic crisis. It may be used second-line if carbimazole is not tolerated.</li><li>Antithyroid drugs should only be initiated on specialist advice, and are typically used:<ul><li>Short-term to restore euthyroidism, for example in toxic nodular goitre, in preparation for definitive treatment with radioactive iodine treatment or thyroid surgery.</li><li>Medium-term with the aim of inducing remission of Graves' disease. A person with newly-diagnosed Graves' disease may be treated with antithyroid drugs for 12–18 months if there is mild and uncomplicated disease. Most people with Graves' disease become euthyroid after 4–8 weeks of treatment with carbimazole. People with severe hyperthyroidism, a large goitre, or recent exposure to iodide may need a longer duration of treatment.</li><li>Long-term if radioactive iodine treatment or surgery is contraindicated or declined.</li></ul></li><li>After euthyroidism is achieved, two different treatment regimes may be used by the specialist, which require regular thyroid function monitoring. For both regimes, the remission rate is about 50% if treatment is continued for 6–18 months and then stopped. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#blood-monitoring-for-specialist-treatments\">Blood monitoring for specialist treatments</a> for more information.<ul><li>Titration-block regime — the dose is adjusted regularly depending on free thyroxine (FT4) measurements. A dose reduction may be needed if the FT4 level falls to low-normal or below the reference range, or the TSH level increases, indicating the development of hypothyroidism. The aim is to titrate to the lowest dose needed to maintain a euthyroid state.</li><li>Block and replace regime — the antithyroid drug blocks the synthesis of thyroid hormone. The FT4 level is monitored and levothyroxine (LT4) is added in when the FT4 is in the reference range. Adjustments to the LT4 dose are made to maintain FT4 levels in the reference range.</li></ul></li><li>The British Thyroid Foundation leaflet <a href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=79ea5976-a0c0-4b92-aa54-528d1158cdb5\" data-hyperlink-id=\"42d58c2f-4457-4e51-b5e8-abc700c1238b\">Your guide to antithyroid drug therapy to treat hyperthyroidism</a> may be helpful.</li></ul><p><strong>Radioactive iodine treatment</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Groot et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><ul><li>Radioactive iodine treatment induces damage of DNA leading to death of thyroid cells, causing a decrease in thyroid function and/or reduction in thyroid size.</li><li>It is a first-line definitive treatment for adults with Graves' disease and those with toxic multinodular goitre.<ul><li>Most people with Graves' disease become euthyroid and then hypothyroid within six weeks to six months after completing radioiodine treatment. People with a large goitre may need high doses or repeated treatments to achieve euthyroidism.</li><li>People have to follow radioprotection measures after treatment, for example close and prolonged contact with children and pregnant women should be avoided for about three weeks after standard-dose radioiodine treatment.</li></ul></li><li>It is contraindicated in people with Graves’ disease with active or severe orbitopathy as it may cause an exacerbation of orbitopathy or de novo development. It is also contraindicated in pregnancy or women planning to become pregnant in the next 4–6 months as it crosses the placenta and can cause severe hypothyroidism in the fetus, and it is contraindicated in breastfeeding women.<ul><li>Women should be advised to avoid becoming pregnant for at least six months after radioactive iodine treatment.</li><li>Men should be advised not to father children for at least four months after radioactive iodine treatment.</li></ul></li><li>The British Thyroid Foundation leaflet <a href=\"http://www.btf-thyroid.org/information/leaflets/39-radioactive-iodine-guide\" data-hyperlink-id=\"094e5fbd-bf51-4465-bb92-a9910051ded4\">Your guide to treatment of an overactive thyroid gland with radioactive iodine</a> may be helpful.</li></ul><p><strong>Thyroid surgery </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><ul><li>Thyroid surgery should ideally be performed by a high-volume thyroid surgeon. Options include total thyroidectomy, or hemithyroidectomy for a single thyroid nodule, in people:<ul><li>To prevent the recurrence of hyperthyroidism.</li><li>With <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">compression symptoms</a> from a large toxic multinodular goitre.</li><li>With a co-existing potentially malignant thyroid nodule.</li><li>Who have not tolerated antithyroid drug treatment or it is ineffective, especially in pregnancy or active Graves' orbitopathy, or if radioactive iodine treatment is unsuitable.</li></ul></li><li>Pre-operative treatment with antithyroid drugs aiming for euthyroidism reduces the risk of thyrotoxic crisis which may be precipitated by surgery.</li><li>Post-operative complications include hypothyroidism, hypocalcaemia due to hypoparathyroidism (often transient), and vocal cord paresis due to damage to the recurrent laryngeal nerve.</li><li>The British Thyroid Foundation leaflet <a href=\"http://www.btf-thyroid.org/information/leaflets/31-thyroid-surgery-guide\" data-hyperlink-id=\"2c8a63d8-f18f-4327-8074-a9910051df79\">Your guide to thyroid surgery</a> may be helpful.</li></ul><!-- end field 128f8631-0528-4d80-b4ca-a7b6d83ca41b --><!-- end item 7b5838b3-65e5-408e-bed3-c7b33c82c960 -->","subChapters":[]},{"id":"c505cdc6-14e0-5c27-833c-c45779357456","slug":"basis-for-recommendation-dba","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 97de3ac3-6049-4209-9ae7-92cefc26241e --><h4>Basis for recommendation</h4><!-- end field 97de3ac3-6049-4209-9ae7-92cefc26241e -->","summary":null,"htmlStringContent":"<!-- begin item dba27ad1-049b-42d8-a049-67c9c5a46075 --><!-- begin field 2f58e4bf-b1b9-4eb3-9aba-5025529abe59 --><p>The recommendations on the management of overt hyperthyroidism are largely based on the National Institute of Health and Care Excellence (NICE) clinical guidelines <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2017</a>] and <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]; the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the European Thyroid Association (ETA) publication <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], the American Thyroid Association (ATA) publication <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>] and on investigating thyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>].</p><h5>Arranging emergency admission for a serious complication</h5><ul><li>This recommendation is based on the ETA publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>], which note that thyrotoxic crisis is potentially life-threatening requiring rapid diagnosis and specialist management.</li></ul><h5>Arranging urgent referral</h5><ul><li>The recommendation to arrange urgent specialist assessment if there is a suspected thyroid-stimulating hormone (TSH)-producing pituitary adenoma or resistance to thyroid hormone is based on the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li><li>The recommendation to arrange urgent referral if thyroid cancer is suspected is based on the NICE clinical guidelines on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2017</a>] and thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. Expert opinion in a review article notes that malignancy is uncommon in functional thyroid nodules causing thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h5>Arranging routine endocrinology referral</h5><ul><li>Expert opinion in a review article notes the importance of confirming the underlying cause of hyperthyroidism including transient and non-transient causes, to arrange further investigations, and make management plans. It notes that transient causes of thyrotoxicosis such as thyroiditis may not need specialist treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h5>Considering prescribing a beta-blocker for adrenergic symptoms</h5><ul><li>The recommendation to consider prescribing a beta-blocker for adrenergic symptoms is based on the NICE clinical guideline on thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the ATA guideline on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], the ETA guideline on Graves' hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].<ul><li>The NICE guideline notes that transient thyrotoxicosis without hyperthyroidism usually only needs supportive treatment with beta-blockers. This approach is supported by the UK joint publication, the ATA guideline, and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>The ATA guideline cites moderate-quality evidence recommending beta-adrenergic blockade in all people with symptomatic thyrotoxicosis, especially older people and those with a resting heart rate in excess of 90 beats per minute or with co-existent cardiovascular disease.</li><li>The ETA guideline notes that beta-blockers can help adrenergic symptoms, especially in the early stages before antithyroid drugs may take effect.</li><li>Expert opinion in review articles note that beta-blockers can help rate control in people with tachycardia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li></ul><h5>Considering seeking specialist advice on antithyroid drug treatment</h5><ul><li>The recommendation to consider prescribing antithyroid drugs along with supportive treatment for adults with hyperthyroidism who are waiting for specialist assessment and further treatment is based on the NICE clinical guideline on thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].<ul><li>NICE states that short-term treatment with antithyroid drugs may be needed until decisions are made about the most appropriate specialist treatment needed, based on the experience and expertise of the NICE guideline development group.</li><li>Expert opinion in a review article states that if a person is symptomatic and a non-transient cause of hyperthyroidism is likely, starting antithyroid drugs in primary care is an option. It recommends seeking specialist advice from an endocrinologist regarding drug dosing and monitoring before they are started [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li><li>The recommendations on the management of a person taking a drug treatment which may be contributing to or causing hyperthyroidism is based on the UK joint publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the ATA guideline on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>].<ul><li>The UK joint publication notes that the management of people with amiodarone-induced hyperthyroidism can be complex and may require additional specialist investigations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>].</li><li>The decision to stop amiodarone in people with thyrotoxicosis should be decided on an individual basis in consultation with the treating cardiologist, depending on the presenting features and possible alternative treatment options [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kravets, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li></ul><h5>Offering advice on sources of information and support</h5><ul><li>This recommendation is based on the NICE clinical guideline on thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul><!-- end field 2f58e4bf-b1b9-4eb3-9aba-5025529abe59 --><!-- end item dba27ad1-049b-42d8-a049-67c9c5a46075 -->","subChapters":[]}]},{"id":"0aa92ac3-3a5e-57d7-81cf-78a1496964fd","slug":"managing-subclinical-hyperthyroidism","fullItemName":"Managing subclinical hyperthyroidism","depth":3,"htmlHeader":"<!-- begin field 8e91f907-0829-4dcb-810a-1d2e57b529a7 --><h3>How should I manage a person with subclinical hyperthyroidism (non-pregnant)?</h3><!-- end field 8e91f907-0829-4dcb-810a-1d2e57b529a7 -->","summary":null,"htmlStringContent":"<!-- begin item 0837a4e1-dd3e-4f65-b517-1006ca877249 --><!-- begin field 2c8d3b01-cabe-43ff-98dd-cc33bc4151b0 --><p><strong>If a person has a confirmed diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/definition/\">subclinical hyperthyroidism</a> following repeat <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">thyroid function tests</a> (TFTs):</strong></p><ul><li><strong>Arrange an urgent referral using a suspected cancer pathway if:</strong><ul><li>A person has a goitre, nodule, or structural change in the thyroid gland, if malignancy is suspected. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/neck-lump/\">Neck lump</a> and <a class=\"topic-reference external-reference\" href=\"/topics/head-neck-cancers-recognition-referral/\">Head and neck cancers - recognition and referral</a> for more information.<ul><li>Note: TFTs are usually normal in people with thyroid cancer.</li></ul></li></ul></li><li><strong>Arrange referral to an endocrinologist </strong>for <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#specialist-investigations-management\">specialist investigations and management</a> if:<ul><li>There are two thyroid-stimulating hormone (TSH) readings lower than 0.1 mU/L at least three months apart <em>and</em></li><li>There is evidence of thyroid disease (for example, a goitre or positive <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/assessment/\">TSH-receptor antibodies</a>) or <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">symptoms</a> of thyrotoxicosis.</li></ul></li><li><strong>Offer advice on sources of information and support,</strong> such as:<ul><li>The British Thyroid Foundation leaflets <a data-hyperlink-id=\"e405521d-0305-4968-889d-ab50009b4bd5\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=87a94572-8698-402e-9e1d-f305b905b089\" target=\"_blank\">Your guide to hyperthyroidism</a> and <a data-hyperlink-id=\"90bb81af-1bca-42d0-b8fc-ab50009b4bf0\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=98f12be4-fa91-402a-847a-a3ae22fa33bd\" target=\"_blank\">Your guide to thyroid function tests</a>.</li></ul></li></ul><!-- end field 2c8d3b01-cabe-43ff-98dd-cc33bc4151b0 --><!-- end item 0837a4e1-dd3e-4f65-b517-1006ca877249 -->","subChapters":[{"id":"1e4a08b3-543b-539c-8231-3d97e12a0310","slug":"basis-for-recommendation-086","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 745fb2fe-6772-4e95-bc86-7c0876e39c89 --><h4>Basis for recommendation</h4><!-- end field 745fb2fe-6772-4e95-bc86-7c0876e39c89 -->","summary":null,"htmlStringContent":"<!-- begin item 086c2308-d5d6-4818-aedc-d06c85f75ad9 --><!-- begin field 53996c8b-026c-4326-ae29-d1218fa5627d --><p>The recommendations on the management of subclinical hyperthyroidism are largely based on the National Institute of Health and Care Excellence (NICE) clinical guidelines <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2017</a>] and <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the European Thyroid Association (ETA) publications <em>G</em><em>uidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>] and <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>]; the American Thyroid Association (ATA) publication <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in a review article on subclinical hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>], on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>], and on investigating thyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>].</p><h5>Urgent referral if cancer is suspected</h5><ul><li>The recommendation to arrange urgent referral if thyroid cancer is suspected is based on the NICE clinical guidelines on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2017</a>] and thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]. Expert opinion in a review article notes that malignancy is uncommon in functional thyroid nodules causing thyrotoxicosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h5>Arranging routine endocrinology referral</h5><ul><li>The NICE clinical guideline found no evidence on the management of subclinical hyperthyroidism, so based its recommendations on the experience and expertise of the NICE guideline development group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].<ul><li>It states treatment may be indicated if subclinical hyperthyroidism is persistent, but noted no good evidence of treatment benefit, so any decision to treat should be based on specialist advice.</li><li>It notes people with very suppressed thyroid-stimulating hormone (TSH) levels and other features suggesting thyroid disease are most likely to gain benefit from treatment.</li><li>It also notes that treatment may improve longterm outcomes and reduce the risk of complications for people with subclinical hyperthyroidism.</li></ul></li><li>This approach is supported by the ETA guidelines on subclinical hyperthyroidism which note that some people with persistent disease may benefit from specialist treatment to reduce symptoms, and to reduce the risk of complications and progression to overt hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>].<ul><li>Expert opinion in a review article notes that the best predictor of risk for progression to overt hyperthyroidism is baseline TSH level. People with a TSH level lower than 0.1 mU/L usually have persistent disease or progression to overt hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li></ul></li><li>The ATA guideline on hyperthyroidism found moderate-quality evidence supporting the treatment of some people with subclinical hyperthyroidism, particularly in older people to avoid the risk of arrhythmias and possible stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li><li>CKS notes that the specific NICE recommendations on who to refer for consideration of treatment differ from those in the ETA guidelines, which list additional age-group and TSH level criteria for treatment, depending on the person's co-morbidities and risk of developing complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>]. This approach is supported by expert opinion in a review article, which also notes the lack of evidence from randomized controlled trials on the effects of treatment on symptoms and complications in people with untreated subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi, 2018</a>].</li></ul><h5>Offering advice on sources of information and support</h5><ul><li>This recommendation is based on the NICE clinical guideline on thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].</li></ul><!-- end field 53996c8b-026c-4326-ae29-d1218fa5627d --><!-- end item 086c2308-d5d6-4818-aedc-d06c85f75ad9 -->","subChapters":[]}]},{"id":"9a76292b-83b2-5cda-a078-70c4104728e4","slug":"managing-suspected-graves-orbitopathy","fullItemName":"Managing suspected Graves' orbitopathy","depth":3,"htmlHeader":"<!-- begin field f3288054-c054-44b4-8c78-6e699b2d7b4f --><h3>How should I manage suspected Graves' orbitopathy?</h3><!-- end field f3288054-c054-44b4-8c78-6e699b2d7b4f -->","summary":null,"htmlStringContent":"<!-- begin item f35a81ee-9476-49b4-8d1f-2d4618c64f7a --><!-- begin field c1462a8c-5bc8-403c-9632-c4ed52003475 --><p><strong>If a diagnosis of Graves' orbitopathy is <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">suspected</a>:</strong></p><ul><li><strong>Arrange emergency admission or seek immediate advice from an ophthalmologist with a special interest in thyroid eye disease, </strong>if a person has a suspected sight-threatening <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">complication</a>, such as:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">Dysthyroid optic neuropathy</a> suggested by deteriorating visual acuity or decreased colour discrimination. </li><li>History of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/diagnosis/diagnosis/\">globe subluxation</a>.</li><li>Corneal exposure (cornea or sclera visible with the eyes closed) increasing the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">corneal ulceration</a>.</li></ul></li><li><strong>Arrange a routine referral to an ophthalmologist with a special interest in thyroid eye disease</strong> (or a joint endocrinology and thyroid eye clinic if available) for all other people.<ul><li>Be aware that this may include eye signs in a person who is euthyroid.</li></ul></li><li><strong>Whilst awaiting specialist assessment, </strong>advise the person on:<ul><li>Smoking cessation, if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>The use of artificial tears to lubricate the eyes. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dry-eye-syndrome/\">Dry eye syndrome</a> for more information.</li><li>Avoidance of irritation and damage to the eyes (for example using dark glasses, avoiding dust, and wearing eye protectors during sleep).</li><li>Elevating the head of the bed (to relieve morning eyelid swelling), if needed.</li></ul></li><li><strong>Provide advice on sources of information and support</strong><strong>,</strong> such as:<ul><li>The Thyroid Eye Disease Charitable Trust (website available at <a href=\"http://tedct.org.uk/\" data-hyperlink-id=\"4e1ec88f-4b28-4315-8e97-a992017bb827\">www.tedct.org.uk</a>), which aims to improve awareness of thyroid eye disease, runs a national telephone helpline (telephone 07469 921782), has a newsletter, and runs meetings for patient education and support.</li><li>The British Thyroid Foundation (website available at <a href=\"http://www.btf-thyroid.org/\" data-hyperlink-id=\"d2ab498d-4934-4cc8-8c84-a992017bb8ec\">www.btf-thyroid.org</a>) which has a patient leaflet <a href=\"http://www.btf-thyroid.org/information/leaflets/36-thyroid-eye-disease-guide\" data-hyperlink-id=\"28371b75-b189-47b0-a951-a992017bba7b\">Your guide to thyroid eye disease</a> and a <a href=\"https://www.btf-thyroid.org/teamed-page\" data-hyperlink-id=\"e171b854-33f7-4534-81de-ab510155dd0e\">Thyroid eye disease early warning card</a> for people with confirmed Graves' disease.</li></ul></li></ul><!-- end field c1462a8c-5bc8-403c-9632-c4ed52003475 --><!-- end item f35a81ee-9476-49b4-8d1f-2d4618c64f7a -->","subChapters":[{"id":"10436028-3858-5737-907a-725ec7f3eb2f","slug":"basis-for-recommendation-86e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bb949138-ba2b-423f-b7ab-4b46e99ce392 --><h4>Basis for recommendation</h4><!-- end field bb949138-ba2b-423f-b7ab-4b46e99ce392 -->","summary":null,"htmlStringContent":"<!-- begin item 86eaedef-be25-4b21-931a-a0297230e7e3 --><!-- begin field b3bcff0b-1df8-4730-a2fc-a674c286b75f --><p>The recommendations on the management of suspected Graves' orbitopathy are largely based on the Royal College of Physicians (RCP) clinical guideline <em>Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>], the joint European Thyroid Association (ETA)/European Group on Graves' orbitopathy (EUGOGO) publication <em>Guidelines on the management of Graves' orbitopathy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>], The European Thyroid Association (ETA) publication <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], the American Thyroid Association (ATA) publication <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</p><h5>Arranging emergency admission if sight-threatening complication</h5><ul><li>The recommendation to arrange emergency admission is based on the fact Graves' orbitopathy can be a medical emergency and sight-threatening if there is severe corneal breakdown, globe subluxation, or severe dysthyroid optic neuropathy. Treatment of dysthyroid optic neuropathy includes high-dose intravenous glucocorticoids and rarely urgent decompression surgery if there is a rapid deterioration in visual function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>]. This approach is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h5>Arranging routine referral</h5><ul><li>The joint ETA/EUGOGO guidelines state that people with Graves' orbitopathy should be referred to a combined thyroid-eye clinic or specialized centre providing endocrinological and ophthalmological expertise [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>]. This approach is supported by the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].<ul><li>In people with active and moderate-to-severe or sight-threatening Graves' orbitopathy, surgery or antithyroid drugs are the preferred treatment options [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li><li>High-dose glucocorticoids may be recommended for moderate-to-severe and active Graves' orbitopathy. Rehabilitative treatment (orbital decompression surgery, squint surgery, or eyelid surgery) is needed in the majority of cases which have been conservatively managed. The type and degree of surgery depends on the amount of disfigurement and/or functional impairment that persists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>].</li><li>Specialist orthoptist referral may provide prisms to help correct troublesome diplopia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>].</li></ul></li><li>The ATA guidelines on hyperthyroidism state that euthyroidism should be rapidly achieved and maintained in people with Graves' orbitopathy or risk factors for the development of orbitopathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>]. The ETA guideline also notes that restoration and stable maintenance of euthyroidism are priorities for people with Graves' orbitopathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>].</li><li>Expert opinion in a review article notes that Graves' orbitopathy may occur in the context of hyperthyroidism, hypothyroidism, or euthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul><h5>Providing advice whilst awaiting specialist assessment</h5><ul><li>The recommendation on smoking cessation is based on the fact that compared with non-smokers, current smokers have a three-fold increased risk of Graves' orbitopathy, and the disease is likely to be more severe and have a poorer prognosis following specialist treatment in current smokers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Wiersinga, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The recommendation to use artificial tears is based on the fact people with Graves' orbitopathy have an increased risk of reduced tear secretion and drying of the ocular surface. Artificial tear products protect the ocular surface and control symptoms from the early stages of the disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>]. This aims to reduce the risk of corneal exposure and prevent corneal ulceration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Perros et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The recommendation on the use of dark glasses is based on the joint ETA/EUGOGO guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bartalena, 2016</a>].</li><li>The recommendation to elevate the head of the bed is pragmatic, based on what CKS considers to be sensible clinical practice. It is also supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Providing advice on sources of information and support</h5><ul><li>This recommendation is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field b3bcff0b-1df8-4730-a2fc-a674c286b75f --><!-- end item 86eaedef-be25-4b21-931a-a0297230e7e3 -->","subChapters":[]}]},{"id":"2162ed0e-e1d9-5c0a-9449-63d5df7f0dfc","slug":"arranging-follow-up","fullItemName":"Arranging follow-up","depth":3,"htmlHeader":"<!-- begin field 2089663a-67bc-4cb4-957f-07bd3ed69a11 --><h3>How should I follow-up a person with hyperthyroidism or subclinical hyperthyroidism?</h3><!-- end field 2089663a-67bc-4cb4-957f-07bd3ed69a11 -->","summary":null,"htmlStringContent":"<!-- begin item 2fd5a871-7741-4ed6-81e3-abbb7766c583 --><!-- begin field 926108c7-365f-4057-9dd2-234892b84fb7 --><ul><li><strong>Advise the person to attend for <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/management/management/#blood-monitoring-for-specialist-treatments\">blood monitoring</a> during and after antithyroid drug treatment, radioactive iodine treatment, or thyroid surgery, as advised by their endocrinologist.</strong><ul><li>Blood monitoring may initially be carried out in secondary care but may subsequently be carried out in primary care.</li><li>Seek specialist advice regarding blood results to guide adjustments to drug therapy (if appropriate), if the person is not under an endocrinology specialist.</li><li>If the person is taking antithyroid drugs, advise them to take medication regularly and to be aware of important adverse effects. See the sections in <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/prescribing-information/\">Prescribing information</a> for more information on drug adverse effects.</li></ul></li><li><strong>If the person is taking carbimazole or propylthiouracil, advise them to:</strong><ul><li>Seek urgent medical advice if they develop possible symptoms of agranulocytosis or neutropenia such as fever, sore throat, mouth ulcers, febrile or non-specific illness, bruising, or malaise, and to stop the medication immediately.<ul><li>Arrange an urgent blood test for differential white cell count to exclude agranulocytosis and neutropenia, and consider seeking specialist advice.</li></ul></li></ul></li><li><strong>If the person is taking carbimazole, advise them to:</strong><ul><li>Seek urgent medical advice if they develop possible symptoms of acute pancreatitis.<ul><li>If acute pancreatitis is suspected on assessment, stop carbimazole immediately and manage appropriately. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/pancreatitis-acute/\">Pancreatitis - acute</a> for more information on suggestive symptoms and management.</li></ul></li></ul></li><li><strong>If the person is taking propylthiouracil, advise them to:</strong><ul><li>Seek urgent medical advice if they develop possible symptoms of liver disease, such as anorexia, nausea, vomiting, fatigue, abominal pain, jaundice, light-coloured stool, dark urine, or itch.<ul><li>Arrange an urgent blood test for liver function tests (LFTs). If there are significant LFT abnormalities, stop propylthiouracil immediately and seek specialist advice. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/jaundice-in-adults/\">Jaundice in adults</a> for more information on recognizing acute liver failure.</li></ul></li></ul></li><li><strong>Seek specialist endocrinology advice or arrange referral to endocrinology, depending on clinical judgement, if:</strong><ul><li>The free thyroxine (FT4) level falls below the reference range, or the thyroid-stimulating hormone (TSH) level is raised, as a dose reduction or drug withdrawal of antithyroid medication may be needed.</li><li>The FT4 level is persistently raised six months after completion of radioactive iodine treatment, as this may indicate suboptimal treatment.</li><li>The TSH level is greater than 20 mU/L for more than one month, as levothyroxine (LT4) replacement therapy may be needed, especially if the person has symptoms of hypothyroidism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li></ul></li><li><strong>If the person has untreated subclinical hyperthyroidism:</strong><ul><li>Consider measuring the TSH level every six months. If the TSH level is outside the reference range, consider measuring free thyroxine (FT4) and free triiodothyronine (FT3) in the same sample.</li><li>Consider stopping TSH monitoring if the TSH level stabilises (2 similar measurements within the reference range 3 to 6 months apart).</li></ul></li><li><strong>Manage any <a class=\"topic-reference internal-reference\" href=\"/topics/hyperthyroidism/background-information/complications/\">complications</a> of hyperthyroidism.</strong><ul><li>The British Thyroid Foundation leaflets <a data-hyperlink-id=\"fd36635a-9087-49e6-9c64-a98c0156d28e\" href=\"http://www.btf-thyroid.org/information/leaflets/30-thyroid-disorders-and-osteoporosis-guide\">Your guide to thyroid disorders and osteoporosis</a> and <a data-hyperlink-id=\"380caf6c-667a-45ba-baa8-ab5e01227b3c\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=2e410ffa-86b2-4513-b861-408991f894db\" target=\"_blank\">Your guide to psychological symptoms and thyroid disorders</a> may be helpful.</li></ul></li></ul><!-- end field 926108c7-365f-4057-9dd2-234892b84fb7 --><!-- end item 2fd5a871-7741-4ed6-81e3-abbb7766c583 -->","subChapters":[{"id":"454e50a4-7685-58d4-8ba6-9f278f9b1b40","slug":"blood-monitoring-for-specialist-treatments","fullItemName":"Blood monitoring for specialist treatments","depth":4,"htmlHeader":"<!-- begin field f14fd863-af3e-4051-8723-5e07105d964e --><h4>Blood monitoring for specialist treatments</h4><!-- end field f14fd863-af3e-4051-8723-5e07105d964e -->","summary":null,"htmlStringContent":"<!-- begin item 6187c3b9-3803-4ef6-8412-69913886bdae --><!-- begin field fa977a7e-c14b-4e86-9aac-3514c1a05855 --><p><strong>Blood monitoring for people on carbimazole and propylthiouracil, or after radioactive iodine treatment or thyroid surgery, should be arranged by the person's endocrinologist who should interpret the results to guide adjustments to the person's treatment regime, if appropriate. The following is provided as a reference guide only.</strong></p><ul><li>Before starting treatment with carbimazole or propylthiouracil<ul><li>Full blood count (FBC) including white cell count and differential, and liver function tests (LFTs) should be checked.</li><li>Do not monitor FBC and LFTs in people taking antithyroid drugs for hyperthyroidism, unless there is a clinical suspicion of agranulocytosis or liver damage.</li></ul></li><li>Monitoring of antithyroid drug regimens<ul><li>Thyroid-stimulating hormone (TSH), free thyroxine (FT4) and free triiodothyronine (FT3) should be checked every 6 weeks until the TSH is within the reference range, then TSH (with cascading to check FT4 and FT3) every 3 months until antithyroid drugs are stopped.</li></ul></li><li>Monitoring after stopping antithyroid drugs<ul><li>TSH (with cascading) within 8 weeks of stopping the drug, then TSH (with cascading) every 3 months for a year, then TSH (with cascading) once a year.</li></ul></li><li>Monitoring after radioactive iodine treatment<ul><li>TSH, FT4 and FT3 levels should be measured every 6 weeks for the first 6 months after treatment until the TSH is within the reference range.</li><li>If the person develops hypothyroidism after treatment and is not on antithyroid drugs, levothyroxine (LT4) replacement therapy should be started. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information on dose titration and thyroid function test (TFT) monitoring.</li><li>If the person remains biochemically euthyroid at 6 months, consider measuring TSH (with cascading) at 9 and 12 months after treatment.</li><li>If the person remains biochemically euthyroid 12 months after treatment, consider measuring the TSH (with cascading) every 6 months unless they develop hypothyroidism.</li><li>If hyperthyroidism persists after treatment, ensure the person is under specialist care.</li></ul></li><li>Monitoring after thyroid surgery<ul><li>If the person has had a total thyroidectomy, LT4 replacement therapy will have been started post-operatively. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information on dose titration and TFT monitoring.</li><li>If the person has had a hemithyroidectomy, TSH may be measured (with cascading) annually, depending on specialist advice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>]</p><!-- end field fa977a7e-c14b-4e86-9aac-3514c1a05855 --><!-- end item 6187c3b9-3803-4ef6-8412-69913886bdae -->","subChapters":[]},{"id":"4041ba41-f1dd-53d4-be92-38f778505121","slug":"basis-for-recommendation-8a6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7c747851-8c19-44c9-b429-9ef383499303 --><h4>Basis for recommendation</h4><!-- end field 7c747851-8c19-44c9-b429-9ef383499303 -->","summary":null,"htmlStringContent":"<!-- begin item 8a697794-ae46-4b9a-b69c-6488251530ec --><!-- begin field 45918426-819f-40cc-aea1-6f0a11a02f94 --><p>The recommendations on follow-up of hyperthyroidism or subclinical hyperthyroidism are largely based on the National Institute of Health and Care Excellence (NICE) clinical guideline <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], the European Thyroid Association (ETA) publications <em>G</em><em>uidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Biondi et al, 2015</a>] and <em>Guideline for the management of Graves' hyperthyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], the American Thyroid Association (ATA) <em>Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>],<strong> </strong>a Medicines and Healthcare products Regulatory Agency (MHRA) drug safety alert <em>Carbimazole: risk of acute pancreatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019a</a>], and expert opinion in review articles on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>] and on investigating thyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>].</p><h5>Advice on when to suspect agranulocytosis and liver damage</h5><ul><li>The recommendations on when to suspect adverse effects from carbimazole and propylthiouracil and action to take are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the ATA guidelines on hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>], the ETA guideline on Graves' hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Kahaly, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].<ul><li>The NICE guideline recommends to stop and not restart any antithyroid drugs if a person develops agranulocytosis, and to consider referral to a specialist for further management options.</li><li>The ATA guidelines highlight the importance of educating people about important drug adverse effects, symptoms to be aware of, and the need to stop any offending drug immediately.</li><li>The ETA guideline on Graves' hyperthyroidism lists potential adverse effects from antithyroid drugs, and advises to give written instructions on the need to stop treatment pending blood test results.</li><li>Antithyroid drug-induced agranulocytosis may be life-threatening. It occurs most commonly in the first three months after starting carbimazole, and is rare after six months of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>The recommendation to stop carbimazole if acute pancreatitis is suspected is based on the MHRA drug safety update [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">MHRA, 2019a</a>].</li><li>Expert opinion in a review article notes that hepatotoxicity occurs in 1 in 1000 people taking propylthiouracil, usually develops within 3 months of starting therapy, and rarely presents as acute liver failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>]. The ATA guidelines note that propylthiouracil can cause fulminant hepatic necrosis that may be fatal, and carbimazole can cause typically cholestatic hepatotoxicity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Ross, 2016</a>].</li></ul></li></ul><h5>Frequency of blood monitoring for specialist treatments</h5><ul><li>The recommendations on blood monitoring are largely based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>], the UK joint publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">BTA et al, 2006</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].<ul><li>Expert opinion in a review article notes that antithyroid drug treatment usually achieves euthyroidism after 3–6 weeks of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li><li>The UK joint publication notes that relapse may occur ten or more years after antithyroid drug treatment has been stopped.</li><li>Expert opinion in a review article notes there is a small risk of hyperthyroidism being exacerbated one month following radioactive iodine treatment, due to the release of pre-formed thyroid hormone, so close blood monitoring is essential. Following this, monitoring is largely aimed at detecting post-treatment hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Vaidya and Pearse, 2014</a>]. Expert opinion in another review article notes that specialist follow-up is needed after radioactive iodine treatment, as levothyroxine (LT4) replacement therapy may be needed if hypothyroidism occurs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">De Leo, 2016</a>].</li><li>Expert opinion in a review article states that specialist follow-up is usually continued until treatment is complete and TFTs are stable post-radioactive iodine or thyroid surgery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Bathgate, 2018</a>].</li></ul></li></ul><h5>Monitoring of untreated subclinical hyperthyroidism</h5><ul><li>The recommendations on thyroid monitoring for people with untreated subclinical hyperthyroidism are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">NICE, 2019</a>].<ul><li>NICE found no good-quality evidence on monitoring this population, so based its recommendations on the experience and expertise of the NICE guideline development group, aiming to identify people who need subsequent treatment of persistent subclinical hyperthyroidism or progression to overt hyperthyroidism.</li></ul></li></ul><h5>Managing complications of hyperthyroidism</h5><ul><li>This recommendation has been extrapolated from expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Weetman, 2013</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 45918426-819f-40cc-aea1-6f0a11a02f94 --><!-- end item 8a697794-ae46-4b9a-b69c-6488251530ec -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}